Today, AIDS is not the bulletproof killer it appeared to be in the 1980s. Current treatments for those infected by the human immunodeficiency virus (HIV), known collectively as Highly Active Antiretroviral Therapy (HAART), have not destroyed the beast, but they have certainly tamed it. Although the infection still claims thousands of lives every year, for the majority of HIV-positive patients it is now a controllable chronic condition.

Yet, while significantly decreasing mortality, HAART is plagued with complications that run the gamut from issues of toxicity and resistance, to patient compliance and adherence to treatment regimens. Nevertheless, PRO 140 from CytoDyn Inc. (OTCQB: CYDY) holds the promise of resolving those issues. PRO 140 is a humanized monoclonal antibody for HIV treatment that, in trials, has shown no serious side effects and hardly any toxicity in over 200 patients.

HAART, in use since 1996, is a combination of different classes of medications that is prescribed based on such factors as the patient’s viral load (how much virus is in the blood), the particular strain of the virus, the CD4+ cell count, and other considerations, and it is designed to slow the rate at which the HIV makes copies of itself. The HIV life cycle, or replication process, takes place in seven stages and particular drugs interfere with the process by attacking one of those stages. HAART, being a ‘cocktail’ of drugs, attacks on several fronts at different stages in the HIV development process.

Various HAART regimens are currently recommended by the U.S. National Institutes of Health (http://nnw.fm/p2iPW). However, because HAART cannot rid the body of HIV, it must be taken every day for life, and that is a tall order for most patients. Consequently, one flaw of HAART is a lack of ‘medication adherence’, or patients not taking HIV medication every day and as exactly as prescribed.

A common reason for this failure to follow doctor’s order is that the drugs used in HAART can be intensely toxic, to the point of being life threatening, with the prescription, in some cases, being just as bad as the malady. Drug resistance further complicates HIV regimens, although, since HAART is a mix of drugs, there is usually less chance of patients developing resistance.

Unlike HAART, which works to slow HIV replication by inhibiting viral enzymes within cells already affected by HIV, a new class of drugs, known as viral entry inhibitors, is being developed to protect healthy cells from HIV infection by blocking early steps in the viral life cycle. PRO 140 works by attaching to the same portion of the CCR5 co-receptor to which HIV normally binds and by blocking the HIV from attaching to the CCR5 co-receptor, thus denying the virus entry.

This mechanism offers distinct advantages over HAART. The normal function of CCR5 is to bind chemokines, or molecules that regulate inflammation. Other HIV drugs that target CCR5 interact with the pocket of the receptor and thereby inhibit binding of both HIV and chemokines, which may have a number of adverse consequences because of the disruption of the chemokine inflammatory response. However, PRO 140 blocks HIV, yet permits normal chemokine binding, potentially leading to less side effects.

Early clinical testing indicates that PRO 140’s half-life contributes to the masking of CCR5 receptors for up to two months. Thus, infrequent dosing with PRO 140 may be possible compared to small molecule drugs, which require daily dosing.

In addition, being an antibody and not a synthetic drug means that PRO 140 will likely (as it has demonstrated in past clinical trials) have fewer issues with toxicity. In addition, previous short- and long-term trials (as long as 2.5 years) have shown that PRO 140 is less likely to induce the development of resistant viruses.

Last December, CytoDyn Inc. announced that several patients had been treated in the first Phase III clinical trial with PRO 140 as a single-agent maintenance therapy in virally suppressed subjects with HIV. PRO 140 is considered one of the most advanced experimental monoclonal antibodies for HIV treatment and has been used in more than 140 HIV-infected subjects in placebo-controlled and open label FDA-approved clinical trials. The drug has been the subject of seven clinical trials, each demonstrating efficacy by significantly reducing or controlling HIV viral load in human test subjects, and it has been designated a “fast track” product by the FDA.

In January, CytoDyn filed a request for Breakthrough Therapy Designation with the FDA for PRO 140 as a treatment for HIV-1 infection in treatment-experienced patients with virologic failure.

For more information, visit www.CytoDyn.com

From its initial founding in 1946 as a brick-and-mortar bookstore in Houston, Texas, ProBility Media Corp. (OTCQB: PBYA) has taken off, migrating its services online to the cloud. As a result, its revenues have moved up, too. The company’s latest filing reports that net sales for the quarter ended January 31, 2017, rose year-over-year by 24 percent. Now the EdTEch company, aiming to become one of the largest providers of skilled trades education and training in the United States, has begun to explore international expansion to the countries that have adopted U.S.-based codes and training. ProBility Media Corp. continues its strategy to build the first full service training and career advancement brand for the skilled trades.

The company’s latest quarterly (10-Q) filing, for the quarter to January 31, 2017, shows management has been aggressive. Apart from achieving record quarterly sales that crossed the million-dollar mark for the first time, they have been actively engaging in the art of the deal by completing two acquisitions, including the acquisition of One Exam Prep LLC, which offers low-cost yet effective exam prep courses in the construction industry. One Exam Prep, based in Coconut Creek, Florida, owns more than 70 domains related to contractor licensing and continuing education and has created hundreds of courses offered either online or in traditional classroom settings in more than 20 states.

ProBility also signed off on its acquisition of Premier Purchasing and Marketing Alliance LLC. Premier, doing business as National Electrical Wholesale Providers (NEWP), services electrical wholesalers throughout the United States with study materials for electricians, including the National Electrical Code. The company provides a complete line of printed reference materials in addition to e-books, downloadable digital formatting and mobile applications to all distributors. NEWP also provides HVAC, plumbing, industrial and residential trade reference materials with online training for product education, certification and current code practices.

NEWP has significant corporate accounts with electrical wholesale conglomerates, making it one of the largest wholesalers of National Electrical Codes in the United States. It services several multibillion-dollar companies such as Consolidated Electrical Distributors and Home Depot, reaching thousands of accounts in locations throughout the United States.

ProBility also signed an exclusive publishing and distribution deal with All Purpose Crane Training (AP), which provides nationwide crane-rigging training and certification that meets OSHA-ANSI requirements. OSHA is the Occupational Safety and Health Administration; ANSI is the American National Standards Institute.

The courses, customized to meet the specific needs of customers, can be taken either at the customer’s site or at AP’s training centers around the country. They include aerial lift operator training, forklift operator certification, crane rigging instructor courses, mobile crane operator certification, crane operator training, overhead crane training, and rigging and signal-person qualification training.

In addition to these major deals, ProBility has entered into two new publishing contracts. The first is with Ralph Dewey, author of the most widely-distributed instrumentation texts in the industry. Titles include The Purdy’s Instrument Handbook, The Purdy’s Instrument Handbook #2, and Dewey’s Troubleshooting Handbook, all of them staples for professionals who operate in instrumentation or related fields. ProBility will also be the exclusive distributor and publisher of the new release of The Purdy’s Instrument Pocket Guide, to be released soon. This guide will include all the highlights from the three handbooks in a pocket-sized edition.

The company’s second contract is with Pat Ginther for his bestselling book, The Sheet Metal Pocket Guide, created for engineers who design in sheet metal and who are looking for the latest techniques and best practices.

ProBility has signaled its rise to the top with an uplisting to the QB Tier of the OTC Markets. To qualify for the listing, a company must demonstrate that it is current in its reporting requirements to the Securities and Exchange Commission and commits to undergo an annual management certification process to verify officers, directors, controlling shareholders and shares outstanding.

ProBility Media Corp. may have taken off, but it hasn’t left transparency behind.

For more information, visit the company’s website at www.ProBilityMedia.com

Let us hear your thoughts: ProBility Media Corp. Message Board

One Step Vending Corp. (OTC: KOSK) is focused on growing through acquisitions and cooperative agreements with companies that have potential and capabilities of achieving sustainable growth and rapidly capturing market share. The company provides financing and operational business support while also helping build key growth strategies. Key business sectors actively targeted include food and refreshment services, self-checkout systems and mobile vending machines.

Corporate Refreshment Services (CRS) Micro Markets Inc., a subsidiary of One Step Vending, is a self-checkout retailer that offers a wide range of food and beverages. Regardless if a traditional vending machine or the high-tech micro market is chosen, the location’s patrons enjoy gourmet market deliciousness and quick market convenience.

Mainly targeting the office environment, the micro markets offer a fresh market-grab and go-food concept that doesn’t cost the business anything to host. Each micro market can be customized for any size or look and feature an easy-to-use touch screen interface so anyone can easily shop, scan and pay for their items. Once installed, employees benefit from a diverse menu that includes healthy snacks, real food, classic vending favorites and much more.

The team behind this concept has been committed to staying at the forefront of vending technology for 15 years. By replacing traditional vending machines with micro markets, they experienced up to five times greater revenue in large accounts. Today, the groundwork is laid with unique capabilities and proven execution strategies.

With CRS Micro Markets Inc. setting the example, One Step Vending’s mission is to support thousands of businesses in the realization of their business goals by delivering experiences that enrich and nourish. Fostering a winning network of associates and partners and building mutually loyalty and trust is core to the company’s growth strategy.

For more information, visit the company’s website at www.OneStepVending.com

Let us hear your thoughts: One Step Vending Corp. Message Board

Most businesses across numerous industries would agree that the internet has disrupted them in one way or another, either positively or negatively. Some believe the internet has led to technological advancements never seen before that have enabled them to cut costs, keep their information safe, and make certain day-to-day tasks easier. Others have seen the internet lead to an increase in unemployment, more space for security breaches, and a lack of human touch when it comes to interactions with consumers.

But how has the proliferation of the internet disrupted those in the real estate industry? Recent studies (http://dtn.fm/0wF0F) show that real estate agents in the U.S. are still receiving their usual 5% to 6% commission on home sales, and, despite the internet having had a negative impact on many of the middlemen from various industries, the commission that real estate agents receive has increased since the early 2000s. Although many assumed real estate agents would struggle because of the internet, the number of agents has actually grown by more than 50% in the past 20 years.

What many have not realized is that the internet has affected the industry as a whole, but has not affected the ever-growing need for agents. The internet has changed the way agents work and interact with their clients for the better, because, although consumers are doing more of the home buying research online, they still have a big decision to make, and therefore turn to agents and brokers for help. More has also been done by real estate companies in terms of advertising to keep the focus on their agents, for example, Century 21’s “Good Luck, Robots” TV commercial (http://dtn.fm/aDtl9).

eXp World Holdings, Inc. (OTCQB: EXPI) is showing the importance of real estate agents and brokers through a different approach, by embracing technology and using it to leverage the ability of agents. The rapidly growing company (its agent roster is expected to double in this year alone) has been referred to as the “Amazon” of real estate. It’s an agent-owned brokerage that has cut out the need for brick and mortar facilities with the use of the cloud, but without cutting out the much-needed agents that run it. Instead of using the internet to replace its brokers and agents, EXPI is using it as a tool to maximize agent-ownership, and agents love it.

EXPI is the first company to ever use 3D, fully immersive cloud-based tools and techniques that allow agents to meet colleagues, share advice, learn through virtual classes, and build strategies to further grow their businesses. EXPI has created this business model not to cut out the middleman, but to show Americans that relying less on traditional offices and adopting technological advancements offer significant benefits to both business growth and customer satisfaction.

For more information, visit the company’s website at www.eXpWorldHoldings.com

Let us hear your thoughts: eXp World Holdings, Inc. Message Board

Net Element (NASDAQ: NETE) management believes that cash transactions are becoming progressively obsolete. The company is in the digital transaction business, with its North American transactions revenue growing to $42.1 million in calendar 2016, up 54% from 2015. Interestingly, for consumer transactions, where restaurants and educational services dominated in 2015, health and beauty was the fastest growing segment last year — accounting for almost 20% of that total business.

Net Element is a global financial services company focusing on processing electronic payments in an omni-channel environment. It has three segments: North American Transaction Solutions, Mobile Payment Solutions, and Online Payment Solutions. In 2016, the North American segment contributed 78% of total corporate revenue of $54.3 million, or ten points higher than in 2015. The company processed $1.6 billion in transactions in this segment in 2016, a 60% increase over its 2015 revenues.

While 48% of Net Element’s processing in North America in 2015 came from restaurants, as its sales team emphasized its Aptito high-technology product line, that figure dropped to 37% last year. In its place was a surge in health and beauty establishment processing. It grew to 19.9% in 2016 from 7.1% in 2015. General merchandise also grew, delivering greater than 15% of all transactions processed last year. Conversely, educational services fell to just 4.4% from 15.9% in 2015.

Net Element has a lot of growth potential in U.S. processing in the health and beauty category. The hair care industry in the U.S. has some 86,000 establishments, including 82,000 beauty salons and 4,000 barber shops, according to a research study titled ‘Beauty Salon Business Overview and Trends, 2014’ (http://nnw.fm/88zsJ). It’s a growing business; revenue is seen reaching $58.7 billion by 2019. Due to the appeal of higher profit margins, industry operators are seen increasing to 1.3 million by 2019. It also sees higher enrollments at cosmetology schools.

For more information, visit www.NetElement.com

The cannabis plant is comprised of, among other things, phytochemicals that have evolved over time to become very biologically active. Most of the current research and development (R&D) surrounding cannabis revolves around understanding these biologically-active ingredients, especially cannabinoids. To date, over 90 cannabinoids have been isolated from cannabis, each affecting the body’s cannabinoid receptors and responsible for distinctive pharmacological effects. The cannabinoids that bind more selectively to certain receptors have become more desirable for medical usage because of the advantage offered. Examples of phytochemicals that have been developed into pharmaceutical drugs include the bronchodilator (asthma), salicin (aspirin) and a number of cardiovascular agents.

InMed Pharmaceuticals is a Canadian drug discovery and development company with a unique focus on this area of cannabinoid science and the curative capabilities of cannabinoids. Since the 1980s, InMed has been developing a robust pipeline of therapies and products by leveraging its primary value drivers: its leadership team and its research and development into the extensive pharmacology of cannabinoids; its proprietary drug discovery platform; its proprietary cannabinoid manufacturing system; and its inventive drug delivery systems.

InMed benefits from the leadership of tested experts like Dr. Ado Muhammed, the company’s Chief Medical Officer. A proven leader in the field of cannabinoid therapies, Muhammed previously served as Associate Medical Director at GW Pharmaceuticals, a $3 billion cannabis biotechnology company. There, he played a strategic role in the delivery of core clinical research and key decision-making regarding R&D and product commercialization. Moreover, he was instrumental in leading that company through the development and regulatory approval of one of the first cannabis drugs in existence. InMed prides itself on being the only cannabis biotech company with a former GW Pharmaceuticals executive on board. This is a significant occurrence, as GW Pharmaceuticals is viewed as “the cannabis industry leader,” as well as a long-term biotech investment with a promising future. Since 2013, GW Pharmaceuticals’ shares have shot up from less than $9 to over $121 as of March 30, 2017, bringing it to a market value of approximately $2.9 billion.

Bioinformatics assessment is another of InMed’s core value drivers. As a general approach, this type of assessment opens up the world for future drug discovery, as it combines scores of data sets and builds holistic models to approach a specific disease. As part of its operations, InMed has created a computer-based program that assists in the discovery of novel cannabinoids using: (a) far-reaching algorithms to integrate data from various bioinformatics databases, (b) a database on the structure of currently-approved pharmaceutical products, and (c) a broad database containing the 90-plus individual cannabinoid drugs that have been found in cannabis. The company is now using this bioinformatics assessment tool to classify bioactive compounds within the cannabis plant that have the potential to have physiological impacts on specific diseases and to, ultimately, identify new drug candidates that heighten the therapeutic benefits of cannabis while restricting its adverse effects.

Biosynthesis — a process used in industrial applications, including the use of bacteria- or yeast-based systems for the production of pharmaceuticals — is also one of InMed’s primary value drivers. InMed is currently building up a high-yield biosynthesis process for manufacturing all 90+ naturally-occurring cannabinoids. This process integrates the inbuilt safety and known effectiveness of natural drug structures with the convenience, control and quality of a laboratory-based manufacturing process. InMed’s proprietary approach to the production of pharmaceutical grade, bio-identical cannabinoids is a disruptive technology in the current and rapidly-emerging cannabinoid pharmaceutical sector.

Along with its proprietary in silico drug/disease bioinformatics assessment tool and its cannabinoid biosynthesis technology, InMed’s drug development pipeline is also a core asset. The company is leveraging a conservative clinical budget and accelerated drug development timelines to target unmet medical conditions using its disease-specific formulations. Presently, the company has two drug candidates in its pipeline:

• INM-750 is under pre-clinical development for the treatment of epidermolysis bullosa, an orphan pediatric disease that is typified by extremely fragile skin. Epidermolysis bullosa has no current approved therapies and represents an estimated $1 billion market.
• INM-085 is under pre-clinical development for the treatment of glaucoma, a severe eye disease with a global market of approximately $5.6 billion.

InMed Pharmaceuticals is also seeking and developing novel drug candidates for the treatment of conditions relating to dermatology, pain and inflammation, metabolic and respiratory diseases, and the ocular region and central nervous system.

For more information, visit the company’s website at www.InMedPharma.com

Let us hear your thoughts: InMed Pharmaceuticals, Inc. Message Board

Grey Cloak Tech, Inc. (OTC: GRCK) is a developer of industry-leading click-fraud detection software designed to overcome the most expensive and devastating threats in the digital world. Through its recently acquired subsidiary, ShareRails, Grey Cloak now also provides sophisticated e-commerce tools that help retailers evolve beyond their brick-and-mortar business practices to increase both their digital engagement and their foot traffic.

ShareRails is an online-to-offline technology firm that provides vitally important services within the trillion-dollar retail sector, helping brick-and-mortar retailers compete directly for online awareness with e-commerce-only brands. Through the ShareRails O2O platform, offline retailers can use online channels to more effectively drive sales and attract new customers.

The innovative solutions offered by ShareRails enable local retailers to capture the millions of online shopping searches they are currently missing out on because their product inventories and other key information is not currently available online and, therefore, does not appear in relevant searches and cannot be viewed digitally.

Most of today’s retail sales are Web-influenced. By utilizing digital marketing channels, merchants can enhance the in-store shopping experience for customers and simultaneously boost sales. The ShareRails O2O platform enables retailers to put their product catalogs online, along with product location and availability, and make the information searchable. The platform also offers digital merchandising tools that include an outfit builder and wishlist app along with conversational shopping tools. Through ShareRails O2O, merchants can additionally tap into data that details shopper insights and behavioral trends. Add-on services include click-n-collect, reservations for in-store pickup, and local delivery.

ShareRails additionally offers Dress.li, which is a recommendation and reward platform that connects shoppers to stylists, bloggers and other fashion influencers who provide them with expert shopping advice and uniquely styled looks and, simultaneously, connects the consumers to fashion retailers. Through Dress.li, the challenge of creating a seamless social shopping experience has finally been mastered! This platform facilitates live shopping communications, curation and content creation and lets users join a global network of trendsetters. Through this network, users can inspire and be inspired, accessing and sharing product recommendations and unique looks and receiving rewards each time another user makes a purchase from their recommendations. This platform not only provides an enjoyable and exciting network for shoppers and fashionistas, but it simultaneously supplies retailers with a lucrative outlet for acquiring new customers through a built-in global sales force of fashion influencers. As these Dress.li stylists create and share looks, they also deliver pre-qualified sales leads and conversions and are rewarded for doing so.

Joined together, Grey Cloak Tech’s industry-leading click-fraud detection solutions and the exciting retail-boosting products delivered through ShareRails offer a broad package of services to both protect businesses in the digital world and help them utilize digital channels to bolster their sales and enhance customer engagement.

Grey Cloak Tech continues to serve as an industry leader in developing the most effective and comprehensive weapons to fight online security threats. The company is keenly focused on protecting its clients’ interests through the identification of fraud patterns at the very earliest stages. When businesses partner with Grey Cloak Tech, they can look forward to benefiting from industry-leading technology, a top-tier client services team, and an augmented bottom line.

For more information, visit the company’s website at www.GreyCloakTech.com

Let us hear your thoughts: Grey Cloak Tech, Inc. Message Board

It’s not just the size, but also the demand and margins involved in the alternative lodging rental (ALR) market that are impressive. Providing a platform where travelers can rent private homes and other non-traditional lodging has proved to be disruptive and transformative to the travel industry. The number of users just keeps growing while home owners and travelers mutually benefit, and the platform providers generate enormous revenues due to higher margins.

The obvious elephant in this arena is Airbnb, which has grown from inception 10 years ago to a valuation of more than $30 billion. Because of the size and demand in the ALR market, other players like HomeAway, Priceline, and FlipKey have staked out territory. Airbnb has about 2.5 million ALR listings in inventory, including homes and rooms of private owners. HomeAway has about 1.2 million ALR listings, while Priceline has around a half million and FlipKey has 700,000. However, unlike hotels, each of these platforms relies on the private property owner to provide confirmation to the traveler, a process which can take days to complete. This doesn’t sit well with travelers trying to nail down travel details. In fact, a recent article in tnooz travel (http://dtn.fm/ULTi5) showed that, no matter how much they may like the economy and locational advantages typically offered by alternative lodging rentals, travelers really desire the convenience and ease of one-stop booking and instant confirmation, as provided by travel agencies.

One upstart travel company is about to deliver exactly what customers want and, in the process, could disrupt and transform the ALR market and perhaps the entire travel industry. Technology-driven Monaker Group, Inc. (OTCQB: MKGI) has more than 60 years of operational experience serving the tourism industry. This has given Monaker valuable insights into how to best serve today’s traveler and how to deliver ALR options on customer terms. Through its flagship ALR brand, NextTrip, Monaker currently offers about a million ALR listings with another 1.8 million-plus listings in process to be delivered to the travel industry’s fastest growing sector. More importantly Monaker Group’s unique ALR platform, NextTrip.com, is the only platform to offer travelers real-time booking of ALR properties, plus full access to traditional travel lodgings and transportation options, effectively encompassing everything needed to plan and organize vacations. By combining immediate ALR confirmation with all other travel options such as airlines, cruises, concierge services, and rental cars, Monaker will be able to provide the first true all-in-one online booking site.

The tnooz article also highlighted some other shortcomings of current ALR platforms. Survey results showed that over half of respondents would find it valuable if online travel agencies offered ALR options, while less than five percent of business travelers were given ALR options and a third would utilize ALR if offered. Presciently, Monaker already addressed these consumer concerns by delivering white label, real-time ALR solutions to Mark Travel and another 85,000 independent travel agents, in addition to providing links to over 200 corporations. Monaker facilitates the complexity of multiple bookings with multiple variations through integration with artificial intelligence travel platforms.

Monaker, given such technical and strategic innovations in an enormous market, represents breakthrough potential at a bargain price for investors. The company trades in the small cap market with about 11 million shares outstanding and about 6 million shares in the float. Estimates show unusually high insider ownership at around 68 percent of the company. That rate of insider ownership suggests that management and other insiders are convinced that they are on the cusp of disrupting and transforming the ALR market and reaping huge rewards in the process.

For more information, visit www.MonakerGroup.com

Now that 28 states have passed comprehensive medical marijuana laws, conditions have never looked better for expanding research and development (R&D) into the therapeutic benefits of cannabinoids, which is exactly what InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) is doing. Its efforts have already borne results: the company has two novel drug candidates in its pipeline. But there’s more to InMed than meets the eye; the Vancouver, Canada-based company has developed a proprietary process to manufacture cannabinoids based on biosynthesis. In addition, it has constructed an algorithm to identify the cannabinoids most likely to have beneficial therapeutic effect. With this triad of core assets, InMed looks poised to join the ranks of Big Pharma.

Of the 480 or so substances found in the cannabis sativa plant, about 60 are unique to the plant and are called cannabinoids. Perhaps the best known of these is delta-9-tetrahydrocannabinol (THC), which is responsible for the ‘high’ derived from marijuana, but cannabinol (CBN) and cannabinodiol (CBDL) will also get you stoned. Most other cannabinoids are not psychoactive and cannabidiol (CBD), the one which occurs the most in the plant (about 40 percent of cannabis resin), actually mitigates the psychoactive effects of THC.

CBD is also known to dispel anxiety, which, according to the Anxiety and Depression Association of America (http://dtn.fm/LUjx9), is the most common mental illness in the U.S., afflicting 40 million Americans. Cannabinoid R&D has the potential not only to ease their suffering but the burden of those who suffer from a variety of other ailments.

At InMed, R&D has led to the development of a proprietary process to manufacture cannabinoids. Traditionally, cannabinoid compounds have been isolated by processing and purifying cannabis resin from actual plants. Alternatively, synthetic cannabinoids are created in the lab in a costly, time-consuming process that, in the end, may not produce a substance quite like nature’s. The InMed approach is to apply cannabinoid DNA to E-coli bacteria. The E-coli DNA is then removed leaving just the cannabinoid DNA, which can then replicate, in a process known as biosynthesis.

Although novel as a means of developing cannabinoids, biosynthesis is widely employed in the pharmaceutical industry. For example, the insulin used by millions of diabetics worldwide on a daily basis is manufactured through biosynthesis.

InMed has also created a bioinformatics program that assists in the identification of novel cannabinoids to treat diseases based on the current non-cannabinoid drugs being used. The program uses comprehensive algorithms to integrate data from numerous bioinformatics databases, including a database on the structure of currently approved pharmaceutical products, and an extensive database on over 90 individual cannabinoid drugs found in cannabis.

Using its own proprietary analytics program and manufacturing methodology, InMed has advanced two drug candidates along its pipeline. The first, INM-750, is for the treatment of a rare genetic connective tissue disorder, called epidermolysis bullosa (EB), that affects roughly one out of every 20,000 births in the United States. The condition, which currently has no approved treatment or cure, has been called “The Worst Disease You’ve Never Heard Of” by the Dystrophic Epidermolysis Bullosa Research Association of America. INM-750 works by replacing missing keratins in the skin with specially selected cannabinoids in an effort to modulate the painful manifestations of EB.

Also in pre-clinical trials is INM-085 for the treatment of glaucoma, a leading cause of blindness, according to the Glaucoma Research Foundation. The drug reduces the elevated intra-ocular pressure that is often associated with glaucoma. It is targeting a large market. The National Institutes of Health estimates that more than 3 million Americans currently have glaucoma, and that the disease has blinded more than 120,000.

InMed continues to expand its cannabinoid R&D. This has already produced huge success for GW Pharmaceuticals (market cap: $3 billion) after its Sativex, derived from cannabis, was approved for the treatment of multiple sclerosis (MS).

For more information, visit the company’s website at www.InMedPharma.com

Let us hear your thoughts: InMed Pharmaceuticals, Inc. Message Board

Player’s Network, Inc. (OTCQB: PNTV) is a fully reporting diversified holdings company, operating in two main industries: medical marijuana and media. The company’s primary objective is to create shareholder value by identifying opportunities in niche emerging markets. PNTV has three prominent subsidiaries: Next Gen TV, WeedTV.com, and Green Leaf Farms, all of which operate under profitable business models.

The primary goal for WeedTV.com is to generate revenues from its proprietary channels and clients. Proprietary channels that Player’s Network is able to generate revenues through include membership subscriptions, advertising, and cross-selling with other organizations. In addition to this, the company’s Next Gen TV gives businesses, brands, and celebrities the tools to create their own network, allowing them to build channels that can be viewed from anywhere.

Player’s Network also owns 86% of Green Leaf Farms Holdings, LLC, better known as Green Leaf. To generate revenue, the company has identified the “best breed” operators to ensure the highest quality of medical marijuana and edibles. These are then legally sold to dispensaries across the state of Nevada. The company is projecting significant revenues, especially for Green Leaf Farms due to recreational marijuana being passed in Nevada.

WeedTV.com, a social media network and informational tool for the marijuana industry, and Green Leaf operate under a unique business model compared to their competitors. Because both are partially or fully owned by Player’s Network, the company combined its knowledge of production, distribution, and marketing, creating a strategy whereby WeedTV.com is able to push Green Leaf products while promoting other companies, leading to two sources of revenue.

Green Leaf is a private company with a Medical Marijuana Establishment license that has 3.4 acres of cultivation and production facilities. In order to maintain high levels of production with its current level of promotion and distribution, Player’s Network aims to continue developing and launching platforms such as WeedTV.com in order to continue expanding its products and services to customers.

For more information, visit the company’s website at www.PlayersNetwork.com

Let us hear your thoughts: Player’s Network, Inc. Message Board